

Oncopeptides announces net sales for Q2 2025

Stockholm, July 9, 2025 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces the net sales for the second quarter of 2025.

Oncopeptides releases this information ahead of the interim report for the second quarter 2025 as net sales are determined by the company to be higher than both the company's projections and assumed market expectations.

"With growth at 45 percent compared to Q1 2025, 135 percent compared to Q2 2024 and 145 percent for the full six months period compared to last year, Q2 2025 supersedes our already high growth ambitions. Q2 marks the third consecutive quarter with a quarter over quarter sales growth above 30 percent, a pace that would take us to profitability by end of next year," says **Sofia Heigis, CEO of Oncopeptides**. "The strong start to 2025 is a testament to our team's operational execution and a growing demand for Pepaxti. We remain focused on sustaining this revenue momentum into the rest of the year and toward profitability by 2026."

Financial overview

- Oncopeptides expects net sales for the second quarter to amount to SEK 19.2 million (SEK 8.2 million for Q2 2024).
- Oncopeptides expects net sales for the six months period to amount to SEK 32.5 million (SEK 13.2 million for the first six months of 2024).

The key reason for the sales increase is stronger-than-expected organic sales growth in Germany, Oncopeptides largest market, combined with faster-than-expected market access in Spain and Italy. The company expects this growth momentum to continue into H2, with the cost base expected to remain at a stable level.

The full Q2 Interim Report will be published on August 21 followed by a webcast and Q&A session on the same day. Details including registration to follow.

For more information, please contact:

David Augustsson, Director of IR and Communications, Oncopeptides AB (publ)

E-mail: ir@oncopeptides.com

Cell phone: +46 76 229 38 68

This information is information that Oncopeptides is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-07-09 11:30 CEST.

About Oncopeptides

Oncopeptides is a Swedish biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers.

The company uses its proprietary Peptide Drug Conjugate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East and Africa and elsewhere.

Oncopeptides is also developing several new compounds based on its two proprietary technology platforms PDC and SPiKE.

The company was founded in 2000, has about 80 employees with operations in Sweden, Germany, Austria, Spain and Italy. Oncopeptides is listed on Nasdaq Stockholm with the ticker ONCO.

For more information see: www.oncopeptides.com

Attachments

[Oncopeptides announces net sales for Q2 2025](#)